Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly? - Sorbonne Université
Journal Articles JAMA neurology Year : 2023

Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?

Abstract

This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.

Domains

Life Sciences [q-bio]
Fichier principal
Vignette du fichier
Are AA DMTs-R2-final Clean v2_HAL.pdf (145.54 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Nicolas VILLAIN  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-04230862

Submitted on : Friday, October 6, 2023-11:51:39 AM

Last modification on : Thursday, November 7, 2024-2:22:15 PM

Download

Dates and versions

hal-04230862 , version 1 (06-10-2023)

Licence

Attribution - NonCommercial - NoDerivatives

Identifiers

Cite

Vincent Planche, Nicolas Villain. Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?. JAMA neurology, 2023, 80 (7), pp.659. ⟨10.1001/jamaneurol.2023.0815⟩. ⟨hal-04230862⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

CNRS ICM SORBONNE-UNIVERSITE SU-MEDECINE
25 View
52 Download

Altmetric

Share

More